MILAN (MF-DJ)–The Rottapharm dossier is back on Clessidra's radar.
The fund promoted by Claudio Sposito, after being included in the five-man short list drawn up in December and then stepping aside, writes MF, has returned to evaluating the opportunity to invest in the pharmaceutical company founded and controlled by entrepreneur Luigi Rovati . The interest, according to what MF-Milano Finanza learned from sources close to the operation, has re-emerged in these hours after the advances of the other suitors, in particular of the American financial group Avista and secondly of Advent and Carlyle, would not have found the total approval of Rovati himself.
If the road to listing on the stock market today seems to be blocked by excessive market fluctuations, that of a strategic alliance with a financial investor becomes the more natural one. And it is on this point that he intends to beat Sposito who is ready to take over a qualified minority stake. Clessidra's goal would be to reach the 40% threshold, leaving the majority to the Rovati family, which for its part does not want to lose control of industrial operations and strategy. The Sposito fund, in particular, would like to shorten the timeframe also to make a significant acquisition after the Avio deal fell through, the participation in the Unipol-Premafin-FonSai deal did not materialize and the operation Twin Set.
red/lab
(END) Dow Jones Newswires
